| Dr John Austin Hancock, MD | |
|
2190 North Loop W, Houston, TX 77018-8129 | |
| (713) 563-7854 | |
| Not Available |
| Full Name | Dr John Austin Hancock |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 18 Years |
| Location | 2190 North Loop W, Houston, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013143015 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0204X | Radiology - Vascular & Interventional Radiology | N3069 (Texas) | Primary |
| 2085R0202X | Radiology - Diagnostic Radiology | N3069 (Texas) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Houston Methodist Hospital | Houston, TX | Hospital |
| Houston Methodist Sugarland Hospital | Sugar land, TX | Hospital |
| Houston Methodist San Jacinto Hospital | Baytown, TX | Hospital |
| Houston Methodist West Hospital | Houston, TX | Hospital |
| Houston Methodist Willowbrook Hospital | Houston, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Houston Radiology Associated | 8022092451 | 109 |
News Archive
Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.
A protein that influences the epigenetic characteristics of tumor cells is directly linked to the grade of malignancy of prostate cancer. This key discovery has been made by a team of scientists from the German Cancer Research Center, the University of Zurich, Hamburg-Eppendorf University Hospital, Heidelberg University, and other institutes in a study of 7,700 samples of tumor tissue.
Transcept Pharmaceuticals, Inc. today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Intermezzo® for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.
"Thanks to today's Senate vote, we are one step closer to bringing much needed reform to our nation's health system," said Georges C. Benjamin, MD, FACP, FACEP (E), executive director of the American Public Health Association.
Responding to Sir Michael Bichard's report into the murders of Holly Wells and Jessica Chapman, Mr Blunkett said the government would act on the main recommendations immediately. He said the report uncovers serious failures in recording and managing information.
› Verified 6 days ago
| Entity Name | Baylor College Of Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053352914 PECOS PAC ID: 8224941265 Enrollment ID: O20031106000562 |
News Archive
Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.
A protein that influences the epigenetic characteristics of tumor cells is directly linked to the grade of malignancy of prostate cancer. This key discovery has been made by a team of scientists from the German Cancer Research Center, the University of Zurich, Hamburg-Eppendorf University Hospital, Heidelberg University, and other institutes in a study of 7,700 samples of tumor tissue.
Transcept Pharmaceuticals, Inc. today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Intermezzo® for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.
"Thanks to today's Senate vote, we are one step closer to bringing much needed reform to our nation's health system," said Georges C. Benjamin, MD, FACP, FACEP (E), executive director of the American Public Health Association.
Responding to Sir Michael Bichard's report into the murders of Holly Wells and Jessica Chapman, Mr Blunkett said the government would act on the main recommendations immediately. He said the report uncovers serious failures in recording and managing information.
› Verified 6 days ago
| Entity Name | Singleton Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538107875 PECOS PAC ID: 6305731118 Enrollment ID: O20040315000385 |
News Archive
Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.
A protein that influences the epigenetic characteristics of tumor cells is directly linked to the grade of malignancy of prostate cancer. This key discovery has been made by a team of scientists from the German Cancer Research Center, the University of Zurich, Hamburg-Eppendorf University Hospital, Heidelberg University, and other institutes in a study of 7,700 samples of tumor tissue.
Transcept Pharmaceuticals, Inc. today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Intermezzo® for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.
"Thanks to today's Senate vote, we are one step closer to bringing much needed reform to our nation's health system," said Georges C. Benjamin, MD, FACP, FACEP (E), executive director of the American Public Health Association.
Responding to Sir Michael Bichard's report into the murders of Holly Wells and Jessica Chapman, Mr Blunkett said the government would act on the main recommendations immediately. He said the report uncovers serious failures in recording and managing information.
› Verified 6 days ago
| Entity Name | Houston Radiology Associated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740228097 PECOS PAC ID: 8022092451 Enrollment ID: O20040615000259 |
News Archive
Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.
A protein that influences the epigenetic characteristics of tumor cells is directly linked to the grade of malignancy of prostate cancer. This key discovery has been made by a team of scientists from the German Cancer Research Center, the University of Zurich, Hamburg-Eppendorf University Hospital, Heidelberg University, and other institutes in a study of 7,700 samples of tumor tissue.
Transcept Pharmaceuticals, Inc. today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Intermezzo® for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.
"Thanks to today's Senate vote, we are one step closer to bringing much needed reform to our nation's health system," said Georges C. Benjamin, MD, FACP, FACEP (E), executive director of the American Public Health Association.
Responding to Sir Michael Bichard's report into the murders of Holly Wells and Jessica Chapman, Mr Blunkett said the government would act on the main recommendations immediately. He said the report uncovers serious failures in recording and managing information.
› Verified 6 days ago
| Entity Name | Baylor College Of Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881026664 PECOS PAC ID: 8022243971 Enrollment ID: O20131030000972 |
News Archive
Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.
A protein that influences the epigenetic characteristics of tumor cells is directly linked to the grade of malignancy of prostate cancer. This key discovery has been made by a team of scientists from the German Cancer Research Center, the University of Zurich, Hamburg-Eppendorf University Hospital, Heidelberg University, and other institutes in a study of 7,700 samples of tumor tissue.
Transcept Pharmaceuticals, Inc. today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Intermezzo® for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.
"Thanks to today's Senate vote, we are one step closer to bringing much needed reform to our nation's health system," said Georges C. Benjamin, MD, FACP, FACEP (E), executive director of the American Public Health Association.
Responding to Sir Michael Bichard's report into the murders of Holly Wells and Jessica Chapman, Mr Blunkett said the government would act on the main recommendations immediately. He said the report uncovers serious failures in recording and managing information.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Austin Hancock, MD 2190 North Loop W, Houston, TX 77018-8129 Ph: () - | Dr John Austin Hancock, MD 2190 North Loop W, Houston, TX 77018-8129 Ph: (713) 563-7854 |
News Archive
Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.
A protein that influences the epigenetic characteristics of tumor cells is directly linked to the grade of malignancy of prostate cancer. This key discovery has been made by a team of scientists from the German Cancer Research Center, the University of Zurich, Hamburg-Eppendorf University Hospital, Heidelberg University, and other institutes in a study of 7,700 samples of tumor tissue.
Transcept Pharmaceuticals, Inc. today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Intermezzo® for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.
"Thanks to today's Senate vote, we are one step closer to bringing much needed reform to our nation's health system," said Georges C. Benjamin, MD, FACP, FACEP (E), executive director of the American Public Health Association.
Responding to Sir Michael Bichard's report into the murders of Holly Wells and Jessica Chapman, Mr Blunkett said the government would act on the main recommendations immediately. He said the report uncovers serious failures in recording and managing information.
› Verified 6 days ago
Dr. Joshua Thomas Blunck, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 7026 Old Katy Rd Ste 276, Houston, TX 77024 Phone: 713-621-7426 Fax: 281-674-8308 | |
Dr. Rohan Samir Shah, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 8305 Knight Rd, Houston, TX 77054 Phone: 713-790-1666 | |
Natalia Solomon, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3310 Richmond Ave, Houston, TX 77098 Phone: 713-797-1919 | |
Osama Mohamad, MD PHD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1515 Holcombe Blvd, Houston, TX 77030 Phone: 713-792-6161 | |
Whitney Boyce, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 6431 Fannin St # 2.116, Houston, TX 77030 Phone: 713-500-7643 | |
Susana Calle, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1515 Holcombe Blvd, Houston, TX 77030 Phone: 713-792-6161 | |
Jonathan N Levine, M.E. Radiology Medicare: Accepting Medicare Assignments Practice Location: 12951 South Fwy, Houston, TX 77047 Phone: 713-526-5771 Fax: 713-526-2036 |